The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients

Glioblastoma multiforme (GBM) remains one of the most devastating tumors, and patients have a median survival of 15 months despite aggressive local and systemic therapy, including maximal surgical resection, radiation therapy, and concomitant and adjuvant temozolomide. The purpose of antineoplastic...

Descripción completa

Detalles Bibliográficos
Autores principales: Poulsen, Hans Skovgaard, Urup, Thomas, Michaelsen, Signe Regner, Staberg, Mikkel, Villingshøj, Mette, Lassen, Ulrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186574/
https://www.ncbi.nlm.nih.gov/pubmed/25298738
http://dx.doi.org/10.2147/CMAR.S39306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186574/
https://www.ncbi.nlm.nih.gov/pubmed/25298738
http://dx.doi.org/10.2147/CMAR.S39306

Ejemplares similares